Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9564565 | 1.00 | TK1 (0.52) | TK1TYMS | |
| SCHEMBL7535867 | 1.00 | TK1 (0.52) | TK1TYMS | |
| SCHEMBL4626081 | 0.93 | TK1 (0.55) | TK1 | |
| SCHEMBL5086844 | 0.90 | TK1 (0.47) | TK1TYMS | |
| SCHEMBL5486404 | 0.90 | LMNA (0.47) | TK1TYMS | |
| SCHEMBL8426287 | 0.90 | TK1 (0.45) | TK1TYMS | |
| SCHEMBL8999406 | 0.90 | TK1 (0.45) | TK1 | |
| SCHEMBL1501551 | 0.90 | TYMS (0.44) | TK1TYMS | |
| SCHEMBL2027058 | 0.89 | LMNA (0.50) | TK1TYMS | |
| SCHEMBL8892073 | 0.89 | TYMS (0.43) | TK1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3221330-B1 | PHOSPHORAMIDITE SYNTHONES FOR THE SYNTHESIS OF SELF-NEUTRALIZING OLIGONUCLEOTIDE COMPOUNDS | ZATA PHARMACEUTICALS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12559517-B2 | Oligonucleotide manufacturing method | AJINOMOTO CO., INC. (JP) | 2026-02-24 | — | — | US | disclosed |
| US-20230193258-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE | 2023-06-22 | — | — | US | disclosed |
| US-11566042-B2 | Phosphoramidite synthones for the synthesis of self-neutralizing oligonucleotide compounds | ZATA Pharmaceuticals, Inc (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220235090-A1 | OLIGONUCLEOTIDE MANUFACTURING METHOD | AJINOMOTO CO., INC. (JP) | 2022-07-28 | — | — | US | disclosed |
| US-20220127300-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | OSAKA UNIVERSITY (JP) | 2022-04-28 | — | — | US | disclosed |
| US-20200354397-A1 | PHOSPHORAMIDITE SYNTHONES FOR THE SYNTHESIS OF SELF-NEUTRALIZING OLIGONUCLEOTIDE COMPOUNDS | ZATA PHARMACEUTICALS INC (US) | 2020-11-12 | — | — | US | disclosed |
| US-10723755-B2 | Phosphoramidite synthones for the synthesis of self-neutralizing oligonucleotide compounds | ZATA PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10378051-B2 | Continuous extension and deblocking in reactions for nucleic acids synthesis and sequencing | ILLUMINA CAMBRIDGE LIMITED (GB) | 2019-08-13 | — | — | US | disclosed |
| US-20180291056-A1 | OLIGONUCLEOTIDE MANUFACTURING METHOD | AJINOMOTO CO., INC. (JP) | 2018-10-11 | — | — | US | disclosed |
| US-4552922-A | POLYMERIC SUPPORTS CARRYING REACTIVE SPECIES; INTERMEDIATE REMOVESONE SPECIES AND CARRIES IT TO SECOND; TWO SPECIES REACT RELEASING INTERMEDIATE | YEDA RESEARCH & DEVELOPMENT CO. LTD. (IL) | 1985-11-12 | — | — | US | disclosed |
| EP-0155950-A1 | OLIGONUCLEOTIDE POLYMERIC SUPPORT SYSTEM. | MOLECULAR BIOSYSTEMS INC (US) | 1985-10-02 | — | — | EP | disclosed |
| WO-1985002628-A1 | NUCLEIC ACID HYBRIDIZATION ASSAY | HRI RESEARCH, INC. (US) | 1985-06-20 | — | — | WO | disclosed |
| WO-1985001051-A1 | OLIGONUCLEOTIDE POLYMERIC SUPPORT SYSTEM | MOLECULAR BIOSYSTEMS, INC. (US) | 1985-03-14 | — | — | WO | disclosed |
| EP-0115613-A2 | DNA sequences, their preparation, plasmids containing these sequences and their use in the synthesis of eukaryotic gene products in prokaryotes | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 1984-08-15 | — | — | EP | disclosed |
| EP-0108387-A1 | Preparation of recombinant growth releasing factors | F. HOFFMANN-LA ROCHE AG (CH) | 1984-05-16 | — | — | EP | disclosed |
| EP-0106434-A1 | Method and apparatus for multipolymer synthesis systems | YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD. (IL) | 1984-04-25 | — | — | EP | disclosed |
| US-4433140-A | Tridecadeoxynucleotide, process for preparation thereof, and use thereof | DR. KARL THOMAE GMBH (DE) | 1984-02-21 | — | — | US | disclosed |
| EP-0083777-A1 | Physiologically active peptide with between 147 and 162 amino acid residues | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1983-07-20 | — | — | EP | disclosed |
| EP-0058954-A2 | Tridecadeoxynucleotide, process for its preparation and the application | Dr. Karl Thomae GmbH (DE) | 1982-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566042-B2 | Phosphoramidite synthones for the synthesis of self-neutralizing oligonucleotide compounds | PNKP, POLI, TYMP | TK1 55/4885TYMS 7/4885 |
| US-20220235090-A1 | OLIGONUCLEOTIDE MANUFACTURING METHOD | RNGTT, IGF2BP2, DCLRE1B | TK1 110/4885TYMS 37/4885 |
| US-20180291056-A1 | OLIGONUCLEOTIDE MANUFACTURING METHOD | RNGTT, IGF2BP2, DCLRE1B | TK1 110/4885TYMS 37/4885 |
| US-20230193258-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | TK1 1889/4885TYMS 996/4885 |
| US-12559517-B2 | Oligonucleotide manufacturing method | POLL, IGF2BP1, POLI | TK1 48/4885TYMS 363/4885 |
| US-10723755-B2 | Phosphoramidite synthones for the synthesis of self-neutralizing oligonucleotide compounds | PNKP, POLI, TYMP | TK1 83/4885TYMS 10/4885 |
| US-20200354397-A1 | PHOSPHORAMIDITE SYNTHONES FOR THE SYNTHESIS OF SELF-NEUTRALIZING OLIGONUCLEOTIDE COMPOUNDS | PNKP, POLI, TYMP | TK1 55/4885TYMS 7/4885 |
| US-20220127300-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | NT5C3B, DUT, RNGTT | TK1 99/4885TYMS 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.